Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436.
about
A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial.Single-Dose Interaction Study of the Arginine Vasopressin Type 1B Receptor Antagonist ABT-436 and Alcohol in Moderate Alcohol Drinkers.TASP0434299: A Novel Pyridopyrimidin-4-One Derivative as a Radioligand for Vasopressin V1B Receptor.
P2860
Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Clinical safety and hypothalam ...... B receptor antagonist ABT-436.
@en
Clinical safety and hypothalam ...... B receptor antagonist ABT-436.
@nl
type
label
Clinical safety and hypothalam ...... B receptor antagonist ABT-436.
@en
Clinical safety and hypothalam ...... B receptor antagonist ABT-436.
@nl
prefLabel
Clinical safety and hypothalam ...... B receptor antagonist ABT-436.
@en
Clinical safety and hypothalam ...... B receptor antagonist ABT-436.
@nl
P2093
P2860
P1433
P1476
Clinical safety and hypothalam ...... B receptor antagonist ABT-436.
@en
P2093
Charles Locke
David A Katz
Katherine A Tracy
Sandeep Dutta
P2860
P2888
P356
10.1007/S00213-015-4089-5
P577
2015-09-26T00:00:00Z